Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy
PHASE2CompletedINTERVENTIONAL
Enrollment
37
Participants
Timeline
Start Date
June 26, 2015
Primary Completion Date
April 30, 2020
Study Completion Date
April 30, 2020
Conditions
Patients With Stage IV or Recurrent Adenocarcinoma of the Lung
Interventions
DRUG
Abraxane
DRUG
Gemcitabine
All Listed Sponsors
lead
Abramson Cancer Center at Penn Medicine
OTHER
NCT02303977 - Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy | Biotech Hunter | Biotech Hunter